(Q44328216)

English

Lipids. Antibodies against PCSK9--a new era of therapy

scientific article published on 20 November 2012

In more languages

edit

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23165073

retrieved

2 December 2017

title

Lipids. Antibodies against PCSK9--a new era of therapy (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

2 December 2017

1 reference

Alexandra King

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23165073

retrieved

2 December 2017

language of work or name

English

0 references

publication date

20 November 2012

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23165073

retrieved

2 December 2017

published in

Nature Reviews Cardiology

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23165073

retrieved

2 December 2017

volume

10

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23165073

retrieved

2 December 2017

issue

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23165073

retrieved

2 December 2017

page(s)

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23165073

retrieved

2 December 2017

cites work

Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 In

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.166

retrieved

21 January 2018

Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.166

retrieved

31 March 2020

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.166

retrieved

31 March 2020

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.166

retrieved

31 March 2020

Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.166

retrieved

31 March 2020

Identifiers

DOI

10.1038/NRCARDIO.2012.166

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23165073

retrieved

2 December 2017

PubMed publication ID

23165073

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23165073

retrieved

2 December 2017

(Q44328216)

Lipids. Antibodies against PCSK9--a new era of therapy

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)